Forum

Clinical Access Program for Bedaquiline for the treatment of drug-resistant tuberculosis

Francesca Conradie, Graeme Meintjes, Jennifer Hughes, Gary Maartens, Hannetjie Ferreira, Sweetness Siwendu, Iqbal Master, Norbert Ndjeka

Abstract


While clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis. In December 2012, a new drug, bedaquiline, was approved by the US Food and Drug Administration. This article documents the process whereby the National Department of Health, Right to Care and Médecins Sans Frontières obtained access to this medication for South Africans who might benefit from subsequent implementation of the Clinical Access to Bedaquiline Programme.


Authors' affiliations

Francesca Conradie, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Graeme Meintjes, Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, South Africa

Jennifer Hughes, Médecins Sans Frontières, Khayelitsha, Cape Town, South Africa

Gary Maartens, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa

Hannetjie Ferreira, MDR/XDR TB Unit, Klerksdorp/Tshepong Complex, North West Province, South Africa

Sweetness Siwendu, Metro TB Hospital Complex, Brooklyn Chest Hospital, Cape Town, South Africa

Iqbal Master, MDR TB Unit, King Dinuzulu Hospital Complex, Durban, South Africa

Norbert Ndjeka, Drug-Resistant TB, TB & HIV National TB Control & Management, National Department of Health, South Africa

Full Text

PDF (89KB)

Keywords

drug-resistant tuberculosis; bedaquilline; compassionate access

Cite this article

South African Medical Journal 2014;104(3):164-166. DOI:10.7196/SAMJ.7263

Article History

Date submitted: 2013-07-12
Date published: 2014-02-06

Article Views

Abstract views: 3097
Full text views: 1965

Comments on this article

*Read our policy for posting comments here